title: Postoperative chemotherapy in elderly patients with advanced gastric cancer.
abstract: OBJECTIVE
  The definitive efficacy of postoperative chemotherapy in elderly patients with advanced gastric cancer has not been established. The aim of this study is to evaluate prognosis in elderly patients with advanced gastric cancer and the effect of postoperative chemotherapy on prognosis.
  
  
  METHODS
  Fifty-three patients, 75 years of age or older who underwent curative surgery for advanced gastric cancer were divided into 14 patients with postoperative chemotherapy (chemotherapy group) and 39 patients without postoperative chemotherapy (control group). Chemotherapy regimens were as follows: oral 5-FU alone (n = 11), intravenous mitomycin plus 5-FU: MF (n = 2), and MF plus oral 5-FU (n = 1). No prior chemotherapy or radiation was given.
  
  
  RESULTS
  There were no significant differences of clinical and pathological backgrounds between the two groups. The rate of death due to recurrent carcinoma was 50.0% in the chemotherapy group and 43.6% in the control group, the difference being insignificant. Although the median survival time of the chemotherapy group (40.4 months) was longer than in the control group (31.7 months), a significant difference did not exist between the groups. The 1-, 3-, and 5-year survival rates did not significantly differ between the chemotherapy group versus the control group, 85.7% versus 82.1%, 42.9% versus 51.3%, and 35.7% versus 46.2%, respectively.
  
  
  CONCLUSIONS
  Postoperative chemotherapy did not contribute to prolong survival in elderly patients with advanced gastric cancer mainly because the incidence of recurrent carcinoma was not reduced.
authors.affiliation: Department of Surgery, Nagano Red Cross Hospital, Nagano, Japan. hanayan@hsp.md.shinshu-u.ac.jp
authors.forename: K
authors.initials: K
authors.lastname: Hanazaki
authors.forename: Y
authors.initials: Y
authors.lastname: Mochizuki
authors.forename: J
authors.initials: J
authors.lastname: Igarashi
authors.forename: S
authors.initials: S
authors.lastname: Yokoyama
authors.forename: H
authors.initials: H
authors.lastname: Sodeyama
authors.forename: Y
authors.initials: Y
authors.lastname: Sode
authors.forename: M
authors.initials: M
authors.lastname: Wakabayashi
authors.forename: N
authors.initials: N
authors.lastname: Kawamura
authors.forename: T
authors.initials: T
authors.lastname: Miyazaki
authors.forename: J
authors.initials: J
authors.lastname: Amano
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D005743:Gastrectomy; D006801:Humans; D008297:Male; D016685:Mitomycin / Q000627:therapeutic use; D011379:Prognosis; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents; D016685:Mitomycin; D005472:Fluorouracil